| [1] |
. Nature，1969，222（5191）：385-386.
|
| [2] |
Wheate NJ，Walker S，Craig GE，et al. The status of platinum anticancer drugs in the clinic and in clinical trials［J］. Dalton Trans，2010，39（35）：8113-8127.
|
| [3] |
Cleare MJ，Hoeschele JD. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum （II） complexes［J］. Bioinorg Chem，1973，2（3）：187-210.
|
| [4] |
Shimada M，Itamochi H，Kigawa J. Nedaplatin：a cisplatin derivative in cancer chemotherapy［J］. Cancer Manag Res，2013，5：67-76.
|
| [5] |
McKeage MJ. Lobaplatin：a new antitumour platinum drug［J］. Expert Opin Investig Drugs，2001，10（1）：119-128.
|
| [6] |
Gately D，Howell S. Cellular accumulation of the anticancer agent cisplatin：a review［J］. Br J Cancer，1993，67（6）：1171-1176.
|
| [7] |
Safaei R，Katano K，Samimi G，et al. Cross-resistance to cisplatin in cells with acquired resistance to copper［J］. Cancer Chemother Pharmacol，2004，53（3）：239-246.
|
| [8] |
Todd RC，Lippard SJ. Inhibition of transcription by platinum antitumor compounds［J］. Metallomics，2009，1（4）：280-291.
|
| [9] |
Zimmermann T，Zeizinger M，Burda JV. Cisplatin interaction with cysteine and methionine，a theoretical DFT study［J］. J Inorg Biochem，2005，99（11）：2184-2196.
|
| [10] |
Fuertes MA，Alonso C，Pérez JM. Biochemical modulation of cisplatin mechanisms of action：enhancement of antitumor activity and circumvention of drug resistance［J］. Chem Rev，2003，103（3）：645-662.
|
| [11] |
Ginson D. Platinum（iv） anticancer prodrugs：hypotheses and facts［J］. Dalton Trans，2016，45（33）：12983-12991.
|
| [12] |
Pendyala L，Krishnan BS，Walsh JR，et al. Studies on the human metabolism of iproplatin［J］. Cancer Chemother Pharmacol，1989，25（1）：10-14.
|
| [13] |
Awuah SG，Zheng YR，Bruno PM，et al. A Pt（IV） pro-drug preferentially targets indoleamine-2，3-dioxygenase，providing enhanced ovarian cancer immuno-chemotherapy［J］. J Am Chem Soc，2015，137（47）：14854-14857.
|
| [14] |
Gandioso A，Shaili E，Massaguer A，et al. An integrin-targeted photoactivatable Pt（IV） complex as a selective anticancer pro-drug：synthesis and photoactivation studies［J］. Chem Commun （Camb），2015，51（44）：9169-9172.
|
| [15] |
Perland E，Fredriksson R. Classification systems of secondary active transporters［J］. Trends Pharmacol Sci，2017，38（3）：305-315.
|
| [16] |
Yonezawa A，Masuda S，Yokoo S，et al. Cisplatin and oxaliplatin，but not carboplatin and nedaplatin，are substrates for human organic cation transporters （SLC22A1-3 and multidrug and toxin extrusion family）［J］. J Pharmacol Exp Ther，2006，319（2）：879-886.
|
| [17] |
Gao J，Wang WY. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells［J］. Chem Biol Interact，2019，297：50-56.
|
| [18] |
Aguilar A. Kidney cancer：OCT2 demethylation cracks open oxaliplatin resistance［J］. Nat Rev Nephrol，2016，12（10）：581.
|
| [19] |
Lasorsa A，Nardella MI，Rosato A，et al. Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs［J］. J Am Chem Soc，2019，141（30）：12109-12120.
|
| [20] |
Zimmermann T，Burda JV. Cisplatin interaction with amino acids cysteine and methionine from gas phase to solutions with constant pH［J］. Interdiscip Sci Comput Life Sci，2010，2（1）：98-114.
|
| [21] |
Liang S，Han LQ，Mu WW，et al. Carboplatin-loaded SMNDs to reduce GSH-mediated platinum resistance for prostate cancer therapy［J］. J Mater Chem B，2018，6（43）：7004-7014.
|
| [22] |
Kimura T，Kambe T. The functions of metallothionein and ZIP and ZnT transporters：an overview and perspective［J］. Int J Mol Sci，2016，17（3）：336.
|
| [23] |
Kawahara B，Ramadoss S，Chaudhuri G，et al. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein［J］. J Inorg Biochem，2019，191：29-39.
|
| [24] |
Fukuda T，Oda K，Wada-Hiraike O，et al. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition［J］. Gynecol Oncol，2015，137（3）：538-545.
|
| [25] |
Zhao L，Li W，Zhou YX，et al. The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP，and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis［J］. Free Radic Biol Med，2015，82：29-41.
|
| [26] |
Ayers PW，Parr RG，Pearson RG. Elucidating the hard/soft acid/base principle：a perspective based on half-reactions［J］. J Chem Phys，2006，124（19）：194107.
|
| [27] |
Chen J，Gao CZ，Zhang Y，et al. Inorganic nano-targeted drugs delivery system and its application of platinum-based anticancer drugs［J］. J Nanosci Nanotechnol，2017，17（1）：1-17.
|
| [28] |
Browning RJ，Reardon PJT，Parhizkar M，et al. Drug delivery strategies for platinum-based chemotherapy［J］. ACS Nano，2017，11（9）：8560-8578.
|
| [29] |
Du J，Cullen JJ，Buettner GR. Ascorbic acid：chemistry，biology and the treatment of cancer［J］. Biochim Biophys Acta，2012，1826（2）：443-457.
|
| [30] |
Michelet F，Gueguen R，Leroy P，et al. Blood and plasma glutathione measured in healthy subjects by HPLC：relation to sex，aging，biological variables，and life habits［J］. Clin Chem，1995，41（10）：1509-1517.
|
| [31] |
Gamcsik MP，Kasibhatla MS，Teeter SD，et al. Glutathione levels in human tumors［J］. Biomarkers，2012，17（8）：671-691.
|
| [32] |
Kennedy L，Sandhu JK，Harper ME，et al. Role of glutathione in cancer：from mechanisms to therapies［J］. Biomolecules，2020，10（10）：E1429.
|
| [33] |
Choi S，Filotto C，Bisanzo M，et al. Reduction and anticancer activity of platinum（IV） complexes［J］. Inorg Chem，1998，37（10）：2500-2504.
|
| [34] |
Gibbons GR，Wyrick S，Chaney SG. Rapid reduction of tetrachloro（D，L-trans）1，2-diaminocyclohexaneplatinum（IV） （tetraplatin） in R/MINI 1640 tissue culture medium［J］. Cancer Res，1989，49（6）：1402-1407.
|
| [35] |
Perez RP，O''Dwyer PJ，Handel LM，et al. Comparative cytotoxicity of CI-973，cisplatin，carboplatin and tetraplatin in human ovarian carcinoma cell lines［J］. Int J Cancer，1991，48（2）：265-269.
|
| [36] |
Schilder RJ，LaCreta FP，Perez RP，et al. Phase I and pharmacokinetic study of ormaplatin （tetraplatin，NSC 363812） administered on a day 1 and day 8 schedule［J］. Cancer Res，1994，54（3）：709-717.
|
| [37] |
Bramwell VH，Crowther D，O''Malley S，et al. Activity of JM9 in advanced ovarian cancer：a phase I-II trial［J］. Cancer Treat Rep，1985，69（4）：409-416.
|
| [38] |
Clavel M，Monfardini S，Gundersen S，et al. Phase II study of iproplatin （CHIP，JM-9） in advanced testicular cancers progressing after prior chemotherapy［J］. Eur J Cancer Clin Oncol，1988，24（8）：1345-1348.
|
| [39] |
Petrelli NJ，Creaven PJ，Herrera L，et al. Phase II trial of continuous-infusion iproplatin （CHIP） and 5-fluorouracil （5-FU） in advanced colorectal carcinoma［J］. Cancer Chemother Pharmacol，1989，23（1）：61-62.
|
| [40] |
Anderson H，Wagstaff J，Crowther D，et al. Comparative toxicity of cisplatin，carboplatin （CBDCA） and iproplatin （CHIP） in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer［J］. Eur J Cancer Clin Oncol，1988，24（9）：1471-1479.
|
| [41] |
Bouchal P，Jarkovsky J，Hrazdilova K，et al. The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo［J］. Proteome Sci，2011，9（1）：68.
|
| [42] |
Zheng YR，Suntharalingam K，Johnstone TC，et al. Pt（IV） prodrugs designed to bind non-covalently to human serum albumin for drug delivery［J］. J Am Chem Soc，2014，136（24）：8790-8798.
|
| [43] |
Zanellato I，Bonarrigo I，Sardi M，et al. Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma［J］. ChemMedChem，2011，6（12）：2287-2293.
|
| [44] |
Kasparkova J，Kostrhunova H，Novakova O，et al. A photoactivatable platinum（IV） complex targeting genomic DNA and histone deacetylases［J］. Angew Chem Int Ed Engl，2015，54（48）：14478-14482.
|
| [45] |
Johnson SW，Swiggard PA，Handel LM，et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells［J］. Cancer Res，1994，54（22）：5911-5916.
|
| [46] |
Wang ZG，Xu ZF，Zhu GY. A platinum（IV） anticancer prodrug targeting nucleotide excision repair to overcome cisplatin resistance［J］. Angew Chem Int Ed Engl，2016，55（50）：15564-15568.
|
| [47] |
Becherel OJ，Jakob B，Cherry AL，et al. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response［J］. Nucleic Acids Res，2010，38（5）：1489-1503.
|
| [48] |
Chen FH，Pei SN，Wang X，et al. Emerging JWA-targeted Pt（IV） prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance［J］. Biochem Biophys Res Commun，2020，521（3）：753-761.
|
| [49] |
Xue X，You S，Zhang Q，et al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction［J］. Mol Pharm，2012，9（3）：634-644.
|
| [50] |
Neumann W，Crews BC，Sárosi MB，et al. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance［J］. ChemMedChem，2015，10（1）：183-192.
|
| [51] |
Oliveira BL，Stenton BJ，Unnikrishnan VB，et al. Platinum-triggered bond-cleavage of pentynoyl amide and N-propargyl handles for drug-activation［J］. J Am Chem Soc，2020，142（24）：10869-10880.
|
| [52] |
Sun T，Lv T，Wu JB，et al. General strategy for integrated bioorthogonal prodrugs：Pt（II）-triggered depropargylation enables controllable drug activation in vivo［J］. J Med Chem，2020，63（22）：13899-13912.
|
百度学术
下载:
